INTERNATIONAL MULTI DISCIPLINARY JOURNAL FOR RESEARCH & DEVELOPMENT
eISSN 2394-6334 Impact factor: 8.854 Volume 13, issue 04 (2026)

BREAKTHROUGH THERAPIES IN TYPE 2 DIABETES: ADVANCED ROLE OF GLP-1 RECEPTOR AGONISTS AND SGLT2 INHIBITORS

Ergasheva Gulshan Tokhirovna

Assistant of the Department of Clinical Sciences

Asian International University, Bukhara, Uzbekistan

E-mail: ergashevagulshantoxirovna@oxu.uz

Abstract

Type 2 diabetes mellitus (T2DM) is a global health challenge characterized by chronic hyperglycemia and associated complications. Recent therapeutic breakthroughs, particularly GLP-1 receptor agonists and SGLT2 inhibitors, have transformed diabetes management. These agents not only reduce blood glucose levels but also provide cardiovascular and renal protection. This article provides a comprehensive review of their mechanisms, clinical efficacy, combination therapy, and future perspectives in modern diabetes care.

Keywords: Type 2 diabetes mellitus, GLP-1 receptor agonists, SGLT2 inhibitors, semaglutide, tirzepatide, cardiovascular protection, renal protection, incretin therapy

Introduction

Type 2 diabetes mellitus is a chronic metabolic disorder involving insulin resistance and impaired pancreatic beta-cell function. Over the past decades, the prevalence of T2DM has increased significantly worldwide due to sedentary lifestyles, obesity, and aging populations. Traditional treatment strategies focused mainly on glycemic control; however, emerging evidence highlights the importance of addressing cardiovascular and renal outcomes in diabetic patients.

Recent pharmacological innovations have introduced a new paradigm in diabetes management. GLP-1 receptor agonists and SGLT2 inhibitors have demonstrated significant improvements not only in glucose control but also in reducing mortality and major complications.

Mechanism of Action of GLP-1 Receptor Agonists (Expanded Version)

Glucagon-like peptide-1 (GLP-1) receptor agonists represent a class of incretin-based therapies that mimic the physiological effects of the endogenous hormone GLP-1, which is secreted by intestinal L-cells in response to nutrient intake. Under normal conditions, GLP-1 plays a critical role in maintaining glucose homeostasis by enhancing insulin secretion in a glucose-dependent manner. However, in patients with type 2 diabetes mellitus, the incretin effect is significantly diminished, necessitating pharmacological intervention.

GLP-1 receptor agonists bind to and activate GLP-1 receptors located on pancreatic beta-cells, thereby stimulating insulin secretion only in the presence of elevated blood glucose levels. This glucose-dependent mechanism significantly reduces the risk of hypoglycemia compared to traditional insulin therapies. At the same time, these agents suppress glucagon secretion from pancreatic alpha-cells, which decreases hepatic glucose production, particularly during the postprandial state.

In addition to their pancreatic effects, GLP-1 receptor agonists exert important actions on the gastrointestinal system. They delay gastric emptying, which slows the absorption of glucose into the bloodstream and contributes to improved postprandial glycemic control. This effect also enhances satiety signals, leading to reduced caloric intake.

A key feature of GLP-1 receptor agonists is their central nervous system activity. These drugs act on hypothalamic appetite-regulating centers, reducing hunger and increasing feelings of fullness. As a result, patients often experience significant weight loss, which further improves insulin sensitivity and metabolic outcomes.

Moreover, GLP-1 receptor agonists have been shown to exert pleiotropic effects beyond glycemic control. They improve endothelial function, reduce oxidative stress, and exert anti-inflammatory effects, all of which contribute to cardiovascular protection. Emerging evidence also suggests beneficial effects on renal function, including reduced albuminuria and slowed progression of diabetic nephropathy. Long-acting GLP-1 receptor agonists, such as semaglutide, provide sustained receptor activation, resulting in more stable glycemic control and greater weight reduction. Tirzepatide, a novel dual agonist targeting both GLP-1 and glucose-dependent insulinotropic polypeptide (GIP) receptors, amplifies these mechanisms, leading to superior metabolic outcomes compared to traditional GLP-1 monotherapy. Overall, the mechanism of action of GLP-1 receptor agonists is multifaceted, involving coordinated effects on pancreatic hormone secretion, gastrointestinal motility, central appetite regulation, and systemic metabolic pathways. This comprehensive mode of action explains their remarkable efficacy in managing type 2 diabetes and associated comorbidities

Semaglutide is one of the most potent GLP-1 receptor agonists, showing significant reductions in HbA1c and body weight. Tirzepatide, a novel dual GIP and GLP-1 receptor agonist, provides even greater metabolic benefits due to its dual mechanism of action.

These drugs act centrally on the hypothalamus, reducing hunger signals and promoting satiety, leading to substantial weight loss. Additionally, they improve insulin sensitivity and reduce inflammation.

Clinical Benefits of GLP-1 Receptor Agonists

GLP-1 receptor agonists provide multiple clinical benefits:

- Reduction in HbA1c levels (up to 2% or more)
- Significant weight loss (up to 15–20% in some patients)
- Appetite suppression and improved metabolic profile
- Reduction in blood pressure and lipid levels

Large clinical trials have demonstrated that semaglutide and tirzepatide significantly reduce cardiovascular events, including myocardial infarction and stroke. These findings have led to updated clinical guidelines recommending GLP-1 receptor agonists for patients with high cardiovascular risk.

Mechanism of Action of SGLT2 Inhibitors

SGLT2 inhibitors, such as empagliflozin and dapagliflozin, work by inhibiting glucose reabsorption in the proximal renal tubules. This results in increased urinary glucose excretion and reduction of blood glucose levels.

Unlike insulin-dependent therapies, SGLT2 inhibitors function independently of insulin, making them particularly effective in insulin-resistant patients. They also reduce intraglomerular pressure and improve renal hemodynamics.

Clinical Benefits of SGLT2 Inhibitors

SGLT2 inhibitors provide several important benefits:

- Reduction in blood glucose levels
- Decrease in body weight
- Lower blood pressure
- Significant reduction in heart failure risk
- Slowing progression of chronic kidney disease

Major clinical trials have confirmed their role in reducing hospitalization for heart failure and improving renal outcomes. These drugs are now widely recommended for patients with T2DM and cardiovascular or renal comorbidities.

Combination Therapy: A New Standard

The combination of GLP-1 receptor agonists and SGLT2 inhibitors represents one of the most effective therapeutic strategies for T2DM. This dual approach targets multiple pathophysiological mechanisms, including insulin resistance, obesity, and cardiovascular risk.

Clinical studies have shown that combination therapy leads to:

- Greater HbA1c reduction
- Enhanced weight loss
- Improved cardiovascular outcomes
- Better renal protection

This synergistic effect makes combination therapy a preferred option for high-risk patients.

Cardiovascular and Renal Protection

One of the most significant breakthroughs in modern diabetes therapy is the recognition that certain antidiabetic drugs provide organ protection. GLP-1 receptor agonists reduce atherosclerosis and inflammation, while SGLT2 inhibitors improve cardiac function and reduce fluid overload.

Together, these therapies significantly decrease the risk of cardiovascular mortality and progression of kidney disease, making them essential components of comprehensive diabetes care.

Future Perspectives

The future of diabetes treatment is focused on personalized medicine and multi-target therapies. New drugs combining incretin effects with additional metabolic pathways are currently under development.

Advances in digital health and artificial intelligence are expected to further optimize treatment strategies. Integration of pharmacological therapy with AI-based monitoring systems will enhance patient outcomes and improve disease management.

Conclusion

GLP-1 receptor agonists and SGLT2 inhibitors have revolutionized the management of type 2

diabetes mellitus. Their ability to provide glycemic control, weight reduction, and cardiovascular and renal protection represents a major paradigm shift in clinical practice. These therapies are expected to remain central to diabetes treatment strategies in the future.

References:

1. American Diabetes Association. (2024). Standards of Medical Care in Diabetes. Diabetes Care.
2. Brownlee, M. (2005). The pathobiology of diabetic complications: a unifying mechanism. Nature.
3. DeFronzo, R. A. (2009). From the triumvirate to the ominous octet: a new paradigm for type 2 diabetes mellitus. Diabetes.
4. Forbes, J. M., & Cooper, M. E. (2013). Mechanisms of diabetic complications. Physiological Reviews.
5. International Diabetes Federation. (2023). IDF Diabetes Atlas.
6. Marso, S. P., et al. (2016). Liraglutide and cardiovascular outcomes in type 2 diabetes. New England Journal of Medicine.
7. Neal, B., et al. (2017). Canagliflozin and cardiovascular and renal events in type 2 diabetes. NEJM.
8. ERGASHEVA, G. T. (2024). OBESITY AND OVARIAN INSUFFICIENCY. *Valeology: International Journal of Medical Anthropology and Bioethics*, *2*(09), 106-111.
9. Ergasheva, G. T. (2024). Modern Methods in the Diagnosis of Autoimmune Thyroiditis. *American Journal of Bioscience and Clinical Integrity*, *1*(10), 43-50.
10. Tokhirovna, E. G. (2024). COEXISTENCE OF CARDIOVASCULAR DISEASES IN PATIENTS WITH TYPE 2 DIABETES. *TADQIQOTLAR. UZ*, *40*(3), 55-62.
11. Toxirovna, E. G. (2024). DETERMINATION AND STUDY OF GLYCEMIA IN PATIENTS WITH TYPE 2 DIABETES MELLITUS WITH COMORBID DISEASES. *TADQIQOTLAR. UZ*, *40*(3), 71-77.
12. Toxirovna, E. G. (2024). XOMILADORLIKDA QANDLI DIABET KELTIRIB CHIQARUVCHI XAVF OMILLARINI ERTA ANIQLASH USULLARI. *TADQIQOTLAR. UZ*, *40*(3), 63-70.
13. Toxirovna, E. G. (2024). QANDLI DIABET 2-TIP VA KOMORBID KASALLIKLARI BO'LGAN BEMORLARDA GLIKEMIK NAZORAT. *TADQIQOTLAR. UZ*, *40*(3), 48-54.
14. Tokhirovna, E. G. (2024). MECHANISM OF ACTION OF METFORMIN (BIGUANIDE) IN TYPE 2 DIABETES. *JOURNAL OF HEALTHCARE AND LIFE-SCIENCE RESEARCH*, *3*(5), 210-216.
15. Tokhirovna, E. G. (2024). THE ROLE OF METFORMIN (GLIFORMIN) IN THE TREATMENT OF PATIENTS WITH TYPE 2 DIABETES MELLITUS. *EUROPEAN JOURNAL OF MODERN MEDICINE AND PRACTICE*, *4*(4), 171-177.
16. Эргашева, Г. Т. (2024). Эффект Применения Бигуанида При Сахарным Диабетом 2 Типа И Covid-19. *Research Journal of Trauma and Disability Studies*, *3*(3), 55-61.
17. Toxirovna, E. G. (2024). QANDLI DIABET 2 TUR VA YURAK QON TOMIR KASALLIKLARINING BEMOLARDA BIRGALIKDA KECHISHI. *ОБРАЗОВАНИЕ НАУКА И ИННОВАЦИОННЫЕ ИДЕИ В МИРЕ*, *38*(7), 202-209.
18. Эргашева, Г. Т. (2024). СОСУЩЕСТВОВАНИЕ ДИАБЕТА 2 ТИПА И СЕРДЕЧНО-СОСУДИСТЫХ ЗАБОЛЕВАНИЙ У ПАЦИЕНТОВ. *ОБРАЗОВАНИЕ НАУКА И ИННОВАЦИОННЫЕ ИДЕИ В МИРЕ*, *38*(7), 219-226.